Belsomra received FDA approval on August 10, 2014 [1].
When does Belsomra's patent expire?
The patent exclusivity for Belsomra is set to expire in December 2025 [2].
What is Belsomra used for?
Belsomra is prescribed to treat insomnia, specifically difficulty with sleep onset and/or sleep maintenance [1].
How does Belsomra work?
Belsomra is a benzodiazepine receptor antagonist that works by selectively blocking the binding of the wake-promoting neurotransmitter orexin to its receptors [1]. This action is believed to reduce the brain's wake drive, thereby facilitating sleep [1].
Are there alternatives to Belsomra for insomnia?
Other medications are available for insomnia treatment, including other hypnotic agents, and non-pharmacological approaches. The choice of treatment often depends on individual patient factors and the specific type of insomnia.
Who manufactures Belsomra?
Belsomra is manufactured by Merck & Co. [3].
What is the difference between Belsomra and Lunesta?
Belsomra (suvorexant) and Lunesta (eszopiclone) are both used to treat insomnia but belong to different drug classes and have distinct mechanisms of action. Belsomra is an orexin receptor antagonist, while Lunesta is a non-benzodiazepine hypnotic agent.
What are the potential side effects of Belsomra?
Common side effects reported with Belsomra include drowsiness, dizziness, and abnormal dreams [1].
Has Belsomra faced any regulatory challenges?
Information regarding specific regulatory challenges or litigation concerning Belsomra's approval or patent status was not provided in the source. DrugPatentWatch.com tracks such information [2].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205143s000lbl.pdf
2. https://drugpatentwatch.com/
3. https://www.drugs.com/availability/belsomra.html